Claims
- 1. A compound of structure (I) ##STR13## in which, R.sup.1 to R.sup.4 are the same or different and are each hydrogen, halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkanoyl or C.sub.1-6 alkoxycarbonyl, RCF.sub.2 O, an ethoxy group substituted by 3 to 5 fluorine atoms;
- R is hydrogen or fluorine;
- m is 1 or 2;
- n is 0 or 1;
- R.sub.5 and R.sup.6 are the same or different and are each C.sub.1-6 alkyl or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a piperidino or morpholino- group; and
- one of R.sup.7 and R.sup.8 is halogen, and the other is hydrogen or C.sub.1-6 alkyl;
- or a pharmaceutically acceptable salt thereof, provided that when R.sup.5 and R.sup.6 are both alkyl, one of R.sup.7 and R.sup.8 is halogen and the other is C.sub.1-6 alkyl.
- 2. A compound as claimed in claim 1 in which n is 1.
- 3. A compound as claimed in claim 2 in which R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a piperidino, or morpholino group.
- 4. A compound as claimed in claim 1 which is: 2-(5-bromo-4-piperidino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 5. A compound as claimed in claim 1 which is: 2-(3-bromo-4-piperidino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 6. A compound as claimed in claim 1 which is: 2-(3-chloro-4-piperidino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 7. A compound as claimed in claim 1 which is: 2-(3-methyl-5-bromo-4-piperidino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 8. A compound as claimed in claim 1 which is: 2-(3-chloro-5-methyl-4-piperidino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 9. A compound as claimed in claim 1 which is: 2-(3-chloro-4-morpholino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 10. A compound as claimed in claim 1 which is: 2-(3-chloro-5-methyl-4-morpholino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 11. A compound as claimed in claim 1 which is: 2-(3-chloro-5-methyl-4-piperidino-2-pyridylmethylsulphinyl)-5-(1, 1,2,3-tetrafluoroethoxy)-(1H)-benzimidazole.
- 12. A compound as claimed in claim 1 which is: 2-(4-morpholino-3-fluoro-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 13. A compound as claimed in claim 1 which is: 2-(4-morpholino-3-fluoro-2-pyridylmethylsulphinyl)-4,5-dimethoxy-(1H)-benzimidazole.
- 14. A compound as claimed in claim 1 which is: 2-(4-morpholino-5-fluoro-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 15. A compound as claimed in claim 1 which is: 2-(4-morpholino-3-methyl-5-fluoro-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 16. A compound as claimed in claim 1 which is: 2-(4-morpholino-3-fluoro-2-pyridylmethylsulphinyl)-5-methyl-6-methoxy-(1H)-benzimidazole.
- 17. A compound as claimed in claim 1 which is 2-(4-dimethylamino-3-chloro-5-methyl-2-pyridylmethylsulphinyl)-5-methoxy-1(H)-benzimidazole.
- 18. A pharmaceutical composition comprising a compound as claimed in claim 1 in association with a pharmaceutically acceptable carrier.
- 19. A pharmaceutical composition comprising a compound as claimed in claim 2, in association with a pharmaceutically acceptable carrier.
- 20. A pharmaceutical composition as claimed in claim 18, in a form suitable for oral administration.
- 21. A pharmaceutical composition as claimed in claim 19, provided with an enteric coating.
- 22. A pharmaceutical composition according to claim 18 in which the compound of structure (I) is 2-(3-chloro-4-morpholino-2-pyridylmethylsulphinyl)-5-methoxy-(1H)-benzimidazole.
- 23. A pharmaceutical composition according to claim 18 in which the compound of structure (I) is 2-(4-dimethylamino-3-chloro-5-methyl-2-pyridylmethylsulphinyl)-5-methoxy-1(H)-benzimidazole.
- 24. A method of inhibiting gastric acid secretion which comprises administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1.
- 25. A method of treatment of gastro-intestinal diseases and other conditions caused or exacerbated by gastric acidity which comprises administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1.
Parent Case Info
This is a continuation of U.S. Ser. No. 092,251 filed Sep. 2, 1987 now abandoned, which is a continuation-in-part of U.S. Ser. No. 044,880 filed Apr. 30, 1987 now abandoned, which is a continuation-in-part of U.S. Ser. No. 790,994 filed Oct. 24, 1985 now abandoned.
US Referenced Citations (4)
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
92251 |
Sep 1987 |
|
Parent |
44880 |
Apr 1987 |
|
Parent |
790994 |
Oct 1985 |
|